Вирус, который сломал планету. Почему SARS-CoV-2 такой особенный и что нам с ним делать (примечания)

Шрифт

Интервал

S. Duffy, «Why are RNA virus mutation rates so damn high?», PloS Biol., vol. 16, no. 8, p. e3000003, Aug. 2018.

C. A. Suttle, «Viruses in the sea», Nature, vol. 437, no. 7057, pp. 356–361, Sep. 2005.

E. Braun and D. Sauter, «Furin-mediated protein processing in infectious diseases and cancer», Clin. Transl. Immunol., vol. 8, no. 8, Jan. 2019.

K. Wang et al., «SARS-CoV-2 invades host cells via a novel route: CD147-spike protein», bioRxiv, p. 2020.03.14.988345, Jan. 2020.

X. Wang et al., «SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion», Cell. Mol. Immunol., Apr. 2020.

H. Wang et al., «SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway», Cell Res., vol. 18, no. 2, pp. 290–301, Feb. 2008.

M. Hoffmann et al., «SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor», Cell, vol. 181, no. 2, pp. 271–280.e8, Apr. 2020.

J. Shang et al., «Cell entry mechanisms of SARS-CoV-2», Proc. Natl. Acad. Sci., vol. 117, no. 21, pp. 11727–11734, May 2020.

E. Braun and D. Sauter, «Furin-mediated protein processing in infectious diseases and cancer», Clin. Transl. Immunol., vol. 8, no. 8, Jan. 2019.

K. Kuba, Y. Imai, and J. M. Penninger, «Multiple Functions of Angiotensin-Converting Enzyme 2 and Its Relevance in Cardiovascular Diseases», Circ. J., vol. 77, no. 2, pp. 301–308, 2013.

T. Ivanova et al., «Optimization of Substrate-Analogue Furin Inhibitors», ChemMedChem, vol. 12, no. 23, pp. 1953–1968, Dec. 2017.

Y. M. Bar-On, A. Flamholz, R. Phillips, and R. Milo, «SARS-CoV-2 (COVID-19) by the numbers», Elife, vol. 9, Apr. 2020.

K. B. Anand, S. Karade, S. Sen, and R. M. Gupta, «SARS-CoV-2: Camazotz’s Curse», Med. J. Armed Forces India, vol. 76, no. 2, pp. 136–141, Apr. 2020.

D. E. Gordon et al., «A SARS-CoV-2 protein interaction map reveals targets for drug repurposing», Nature, vol. 583, no. 7816, pp. 459–468, Jul. 2020.

Y. Zhang et al., «The ORF8 Protein of SARS-CoV-2 Mediates Immune Evasion through Potently Downregulating MHC–I», bioRxiv, p. 2020.05.24.111823, Jan. 2020.

A. B. Gussow, N. Auslander, G. Faure, Y. I. Wolf, F. Zhang, and E. V. Koonin, «Genomic determinants of pathogenicity in SARS-CoV-2 and other human coronaviruses», Proc. Natl. Acad. Sci., vol. 117, no. 26, pp. 15193–15199, Jun. 2020.

M. J. Costello, R. M. May, and N. E. Stork, «Can We Name Earth’s Species Before They Go Extinct?» Science, vol. 339, no. 6118, pp. 413–416, Jan. 2013.

K. J. Locey and J. T. Lennon, «Scaling laws predict global microbial diversity», Proc. Natl. Acad. Sci., vol. 113, no. 21, pp. 5970–5975, May 2016.

Y. Ikeda, «Feline Host Range of Canine parvovirus: Recent Emergence of New Antigenic Types in Cats», Emerg. Infect. Dis., vol. 8, no. 4, pp. 341–346, Apr. 2002.

É. Leal et al., «Regional adaptations and parallel mutations in Feline panleukopenia virus strains from China revealed by nearly-full length genome analysis», PLoS One, vol. 15, no. 1, p. e0227705, Jan. 2020.

K. E. Jones et al., «Global trends in emerging infectious diseases», Nature, vol. 451, no. 7181, pp. 990–993, Feb. 2008.

Там же.

W. Li, «Bats Are Natural Reservoirs of SARS-Like Coronaviruses», Science (80-.)., vol. 310, no. 5748, pp. 676–679, Oct. 2005.

N. Wang et al., «Serological Evidence of Bat SARS-Related Coronavirus Infection in Humans, China», Virol. Sin., vol. 33, no. 1, pp. 104–107, Feb. 2018.

Y.-Y. Shen, L. Liang, Z.-H. Zhu, W.-P. Zhou, D. M. Irwin, and Y.-P. Zhang, «Adaptive evolution of energy metabolism genes and the origin of flight in bats», Proc. Natl. Acad. Sci., vol. 107, no. 19, pp. 8666–8671, May 2010.

J. Xie et al., «Dampened STING-Dependent Interferon Activation in Bats», Cell Host Microbe, vol. 23, no. 3, pp. 297–301.e4, Mar. 2018.

M. Ahn, J. Cui, A. T. Irving, and L.-F. Wang, «Unique Loss of the PYHIN Gene Family in Bats Amongst Mammals: Implications for Inflammasome Sensing», Sci. Rep., vol. 6, no. 1, p. 21722, Feb. 2016.

E. Ryan, R. Hollingworth, and R. Grand, «Activation of the DNA Damage Response by RNA Viruses», Biomolecules, vol. 6, no. 1, p. 2, Jan. 2016.

C. E. Brook et al., «Accelerated viral dynamics in bat cell lines, with implications for zoonotic emergence», Elife, vol. 9, Feb. 2020.

K. Xiao et al., «Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins», Nature, May 2020.

V. D. Menachery et al., «A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence», Nat. Med., vol. 21, no. 12, pp. 1508–1513, Dec. 2015.

M. F. Boni et al., «Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic», Nat. Microbiol., Jul. 2020.

D. Lim and B. Ehley, «Fauci says White House told NIH to cancel funding for bat virus study», Politico, 23-Jun-2020.

«NIH establishes Centers for Research in Emerging Infectious Diseases», National Institutes of Health, 27-Aug-2020.

A. W. H. Chin et al., «Stability of SARS-CoV-2 in different environmental conditions», The Lancet Microbe, vol. 1, no. 1, p. e10, May 2020.

S. Li et al., «COVID-19 receptor ACE2 is expressed in human conjunctival tissue, expecially in diseased conjunctival tissue», medRxiv, p. 2020.05.21.20109652, Jan. 2020.

N. van Doremalen et al., «Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1», N. Engl. J. Med., vol. 382, no. 16, pp. 1564–1567, Apr. 2020.

K. G. Lokugamage, A. Hage, C. Schindewolf, R. Rajsbaum, and V. D. Menachery, «SARS-CoV-2 is sensitive to type I interferon pretreatment», bioRxiv, p. 2020.03.07.982264, Jan. 2020.

L. Ferretti et al., «Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing», Science, vol. 368, no. 6491, p. eabb6936, May 2020.

J. L. Santarpia et al., «Transmission Potential of SARS-CoV-2 in Viral Shedding Observed at the University of Nebraska Medical Center», medRxiv, p. 2020.03.23.20039446, Jan. 2020.

Z.-D. Guo et al., «Aerosol and Surface Distribution of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, 2020», Emerg. Infect. Dis., vol. 26, no. 7, Jul. 2020.

L. Ferretti et al., «Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing», Science, vol. 368, no. 6491, p. eabb6936, May 2020.

X. He et al., «Temporal dynamics in viral shedding and transmissibility of COVID-19», Nat. Med., vol. 26, no. 5, pp. 672–675, May 2020.

T. Ganyani et al., «Estimating the generation interval for coronavirus disease (COVID-19) based on symptom onset data, March 2020», Eurosurveillance, vol. 25, no. 17, Apr. 2020.

R. Wölfel et al., «Virological assessment of hospitalized patients with COVID-2019», Nature, Apr. 2020.

J. J. A. van Kampen et al., «Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants», medRxiv, p. 2020.06.08.20125310, Jan. 2020.

S. Asadi, A. S. Wexler, C. D. Cappa, S. Barreda, N. M. Bouvier, and W. D. Ristenpart, «Aerosol emission and superemission during human speech increase with voice loudness», Sci. Rep., vol. 9, no. 1, p. 2348, Dec. 2019.

H. Streeck et al., «Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event», medRxiv, p. 2020.05.04.20090076, Jan. 2020.

X. Xie, Y. Li, H. Sun, and L. Liu, «Exhaled droplets due to talking and coughing», J. R. Soc. Interface, vol. 6, no. suppl_6, Dec. 2009.

V. Knight, «Viruses as Agents of Airborne Contagion», Ann. N. Y. Acad. Sci., vol. 353, no. 1, pp. 147–156, Dec. 1980.

R. Wölfel et al., «Virological assessment of hospitalized patients with COVID-2019», Nature, Apr. 2020.

V. Stadnytskyi, C. E. Bax, A. Bax, and P. Anfinrud, «The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission», Proc. Natl. Acad. Sci., p. 202006874, May 2020.

X. Xie, Y. Li, H. Sun, and L. Liu, «Exhaled droplets due to talking and coughing», J. R. Soc. Interface, vol. 6, no. suppl_6, Dec. 2009.

T. C. Jones et al., «An analysis of SARS-CoV-2 viral load by patient age», medRxiv, p. 2020.06.08.20125484, Jan. 2020.

E. L. Anderson, P. Turnham, J. R. Griffin, and C. C. Clarke, «Consideration of the Aerosol Transmission for COVID-19 and Public Health», Risk Anal., vol. 40, no. 5, pp. 902–907, May 2020.

N. van Doremalen et al., «Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1», N. Engl. J. Med., vol. 382, no. 16, pp. 1564–1567, Apr. 2020.

NDR, «(40) Jetzt ist Alltagsverstand gefragt», Das Coronavirus-Update mit Christian Drosten — 12.05.2020 14:00 Uhr Autor/in: Korinna Hennig, 2020. [Online]. Available: https://www.ndr.de/nachrichten/info/40-Jetzt-ist-Alltagsverstand-gefragt,podcastcoronavirus208.html.

L. Morawska and D. K. Milton, «It is Time to Address Airborne Transmission of COVID-19», Clin. Infect. Dis., Jul. 2020.

W. Wang et al., «Detection of SARS-CoV-2 in Different Types of Clinical Specimens», JAMA, Mar. 2020.

W. X. Yong Zhang, Cao Chen, Shuangli Zhu, Chang Shu, Dongyan Wang, Jingdong Song, Jingdong Song, Yang Song, Wei Zhen, Zijian Feng, Guizhen Wu, Jun Xu, «Isolation of 2019-nCoV from a Stool Specimen of a Laboratory-Confirmed Case of the Coronavirus Disease 2019 (COVID-19)», China CDC Wkly., vol. 2, no. 8, pp. 123–124, 2020.

K. Kam et al., «A Well Infant With Coronavirus Disease 2019 With High Viral Load», Clin. Infect. Dis., Feb. 2020.

S. Westhaus et al., «Detection of SARS-CoV-2 in raw and treated wastewater in Germany — Suitability for COVID-19 surveillance and potential transmission risks», Sci. Total Environ., vol. 751, p. 141750, Jan. 2021.

S. Wurtzer et al., «Evaluation of lockdown impact on SARS-CoV-2 dynamics through viral genome quantification in Paris wastewaters», medRxiv, p. 2020.04.12.20062679, Jan. 2020.

G. Medema, L. Heijnen, G. Elsinga, R. Italiaander, and A. Brouwer, «Presence of SARS-Coronavirus-2 RNA in Sewage and Correlation with Reported COVID-19 Prevalence in the Early Stage of the Epidemic in The Netherlands», Environ. Sci. Technol. Lett., vol. 7, no. 7, pp. 511–516, Jul. 2020.

S. Lee, «The SARS epidemic in Hong Kong», J. Epidemiol. Community Health, vol. 57, no. 9, pp. 652–654, 2003.

D. Fisman, «Seasonality of viral infections: mechanisms and unknowns», Clin. Microbiol. Infect., vol. 18, no. 10, pp. 946–954, Oct. 2012.

E. Kudo et al., «Low ambient humidity impairs barrier function and innate resistance against influenza infection», Proc. Natl. Acad. Sci., vol. 116, no. 22, pp. 10905–10910, May 2019.

M. K. Ijaz, A. H. Brunner, S. A. Sattar, R. C. Nair, and C. M. Johnson-Lussenburg, «Survival Characteristics of Airborne Human Coronavirus 229E», J. Gen. Virol., vol. 66, no. 12, pp. 2743–2748, Dec. 1985.

I. V. Polozov, L. Bezrukov, K. Gawrisch, and J. Zimmerberg, «Progressive ordering with decreasing temperature of the phospholipids of influenza virus», Nat. Chem. Biol., vol. 4, no. 4, pp. 248–255, Apr. 2008.

Там же.

A. Lamarre and P. J. Talbot, «Effect of pH and temperature on the infectivity of human coronavirus 229E», Can. J. Microbiol., vol. 35, no. 10, pp. 972–974, Oct. 1989.

J. G. B. Derraik, W. A. Anderson, E. A. Connelly, and Y. C. Anderson, «Rapid evidence summary on SARS-CoV-2 survivorship and disinfection, and a reusable PPE protocol using a double-hit process», medRxiv, p. 2020.04.02.20051409, Jan. 2020.

M. Schuit et al., «The Influence of Simulated Sunlight on the Inactivation of Influenza Virus in Aerosols», J. Infect. Dis., vol. 221, no. 3, pp. 372–378, Jan. 2020.

H. Qian, T. Miao, L. LIU, X. Zheng, D. Luo, and Y. Li, «Indoor transmission of SARS-CoV-2», medRxiv, p. 2020.04.04.20053058, Jan. 2020.

H. Nishiura et al., «Closed environments facilitate secondary transmission of coronavirus disease 2019 (COVID-19)», medRxiv, p. 2020.02.28.20029272, Jan. 2020.

«Coronavirus in the U. S.: Latest Map and Case Count. Hundreds of thousands of cases traced to clusters», The New York Times, 2020. [Online]. Available: https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html#clusters. [Accessed: 26-Jul-2020].

«Dog face mask sales skyrocket in China amid coronavirus crisis», ANI, 21-Jan-2020.

Россельхознадзор из-за коронавируса предложил запретить мероприятия с животными // Интерфакс. 2020. 14 февр.

J. Shi et al., «Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS — coronavirus 2», Science, p. eabb7015, Apr. 2020.

T. H. C. Sit et al., «Infection of dogs with SARS-CoV-2», Nature, May 2020.

E. I. Patterson et al., «Evidence of exposure to SARS-CoV-2 in cats and dogs from households in Italy», bioRxiv, p. 2020.07.21.214346, Jan. 2020.

J. Shi et al., «Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS — coronavirus 2», Science, p. eabb7015, Apr. 2020.

N. Oreshkova et al., «SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020», Eurosurveillance, vol. 25, no. 23, Jun. 2020.

M. Enserink, «Coronavirus rips through Dutch mink farms, triggering culls to prevent human infections», Science, Jun. 2020.

D. F. Maron, «Coronavirus is killing the Dutch mink industry», National Geographic, 24-Jun-2020.

«Coronavirus: Spain orders culling of almost 100,000 mink», BBC, 17-Jul-2020.

T. Enkirch and V. von Messling, «Ferret models of viral pathogenesis», Virology, vol. 479–480, pp. 259–270, May 2015.

Y. Wan, J. Shang, R. Graham, R. S. Baric, and F. Li, «Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus», J. Virol., vol. 94, no. 7, Jan. 2020.

X. Zhai et al., «Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts», J. Virol., vol. 94, no. 15, May 2020.

W. Sungnak et al., «SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes», Nat. Med., vol. 26, no. 5, pp. 681–687, May 2020.

S. Lukassen et al., «SARS-CoV-2 receptor ACE 2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells», EMBO J., vol. 39, no. 10, May 2020.

Y. J. Hou et al., «SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract», Cell, May 2020.

W. Zeng et al., «Association of Daily Wear of Eyeglasses With Susceptibility to Coronavirus Disease 2019 Infection», JAMA Ophthalmol., Sep. 2020.

M. M. Lamers et al., «SARS-CoV-2 productively infects human gut enterocytes», Science, p. eabc1669, May 2020.

S. Lukassen et al., «SARS-CoV-2 receptor ACE 2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells», EMBO J., vol. 39, no. 10, May 2020.

B. Lin et al., «Significant expression of FURIN and ACE2 on oral epithelial cells may facilitate the efficiency of 2019-nCov entry», bioRxiv, p. 2020.04.18.047951, Jan. 2020.

K. K.-W. To et al., «Consistent Detection of 2019 Novel Coronavirus in Saliva», Clin. Infect. Dis., Feb. 2020.

100

L. Azzi et al., «Saliva is a reliable tool to detect SARS-CoV-2», J. Infect., Apr. 2020.

101

R. Lo Giudice, «The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2) in Dentistry. Management of Biological Risk in Dental Practice», Int. J. Environ. Res. Public Health, vol. 17, no. 9, p. 3067, Apr. 2020.

102

L. Zhou et al., «Systemic analysis of tissue cells potentially vulnerable to SARS-CoV-2 infection by the protein-proofed single-cell RNA profiling of ACE2, TMPRSS2 and Furin proteases», bioRxiv, p. 2020.04.06.028522, Jan. 2020.

103

A. Khalil et al., «SARS-CoV-2 infection in pregnancy: A systematic review and meta-analysis of clinical features and pregnancy outcomes», EClinicalMedicine, p. 100446, Jul. 2020.

104

R. Pique-Regi et al., «Does the human placenta express the canonical cell entry mediators for SARS-CoV-2?» Elife, vol. 9, Jul. 2020.

105

M. Li, L. Chen, J. Zhang, C. Xiong, and X. Li, «The SARS-CoV-2 receptor ACE2 expression of maternal-fetal interface and fetal organs by single-cell transcriptome study», PLoS One, vol. 15, no. 4, p. e0230295, Apr. 2020.

106

A. J. Vivanti et al., «Transplacental transmission of SARS-CoV-2 infection», Nat. Commun., vol. 11, no. 1, p. 3572, Dec. 2020.

107

H. Hosier et al., «SARS-CoV-2 infection of the placenta», J. Clin. Invest., Jun. 2020.

108

K. Wang et al., «SARS-CoV-2 invades host cells via a novel route: CD147-spike protein», bioRxiv, p. 2020.03.14.988345, Jan. 2020.

109

U. Radzikowska et al., «Distribution of ACE2, CD147, CD26 and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors», Allergy, p. all.14429, Jun. 2020.

110

C. Cervia et al., «Systemic and mucosal antibody secretion specific to SARS-CoV-2 during mild versus severe COVID-19», bioRxiv, p. 2020.05.21.108308, Jan. 2020.

111

M. W. Russell, «Biological Functions of IgA», in Mucosal Immune Defense: Immunoglobulin A, C. S. Kaetzel, Ed. Boston, MA: Springer US, 2007, pp. 144–172.

112

C. Cervia et al., «Systemic and mucosal antibody secretion specific to SARS-CoV-2 during mild versus severe COVID-19», bioRxiv, p. 2020.05.21.108308, Jan. 2020.

113

N. Le Bert et al., «SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls», Nature, vol. 584, no. 7821, pp. 457–462, Aug. 2020.

114

J. Braun et al., «SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19», Nature, Jul. 2020.

115

E. Kudo et al., «Low ambient humidity impairs barrier function and innate resistance against influenza infection», Proc. Natl. Acad. Sci., vol. 116, no. 22, pp. 10905–10910, May 2019.

116

D. P. Oran and E. J. Topol, «Prevalence of Asymptomatic SARS-CoV-2 Infection», Ann. Intern. Med., pp. M20–3012, Jun. 2020.

117

Q.-X. Long et al., «Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections», Nat. Med., Jun. 2020.

118

K. K.-W. To et al., «COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing», Clin. Infect. Dis., Aug. 2020.

119

A. Woodward and H. Brueck, «2 more people have been reinfected with the coronavirus, European scientists say, a day after the first confirmed reinfection in Hong Kong», Business Insider, 25-Aug-2020.

120

C. Weemaes, I. Klasen, J. Goertz, M. Beldhuis-Valkis, O. Olafsson, and A. Haraldsson, «Development of Immunoglobulin A in Infancy and Childhood», Scand. J. Immunol., vol. 58, no. 6, pp. 642–648, Dec. 2003.

121

K. W. Leong and J. L. Ding, «The Unexplored Roles of Human Serum IgA», DNA Cell Biol., vol. 33, no. 12, pp. 823–829, Dec. 2014.

122

K. Chen et al., «Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell — stimulating programs in basophils», Nat. Immunol., vol. 10, no. 8, pp. 889–898, Aug. 2009.

123

T. Sekine et al., «Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19», bioRxiv, p. 2020.06.29.174888, Jan. 2020.

124

T. Sekine et al., «Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19», Cell, Aug. 2020.

125

F. Wu et al., «Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications», medRxiv, p. 2020.03.30.20047365, Jan. 2020.

126

Q.-X. Long et al., «Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections», Nat. Med., Jun. 2020.

127

Q. Ye, B. Wang, and J. Mao, «The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19», J. Infect., vol. 80, no. 6, pp. 607–613, Jun. 2020.

128

X. Cao, «COVID-19: immunopathology and its implications for therapy», Nat. Rev. Immunol., vol. 20, no. 5, pp. 269–270, May 2020.

129

N. Mangalmurti and C. A. Hunter, «Cytokine Storms: Understanding COVID-19», Immunity, vol. 53, no. 1, pp. 19–25, Jul. 2020.

130

D. Blanco-Melo et al., «Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19», Cell, May 2020.

131

Y. Konno et al., «SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is further increased by a naturally occurring elongation variant», bioRxiv, p. 2020.05.11.088179, Jan. 2020.

132

Там же.

133

D. Mercatelli and F. M. Giorgi, «Geographic and Genomic Distribution of SARS-CoV-2 Mutations», Front. Microbiol., vol. 11, Jul. 2020.

134

K. G. Lokugamage, A. Hage, C. Schindewolf, R. Rajsbaum, and V. D. Menachery, «SARS-CoV-2 is sensitive to type I interferon pretreatment», bioRxiv, p. 2020.03.07.982264, Jan. 2020.

135

«Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection», ClinicalTrials.gov, 2020.

136

X. Yang et al., «Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study», Lancet Respir. Med., vol. 8, no. 5, pp. 475–481, May 2020.

137

V. O. Puntmann et al., «Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19)», JAMA Cardiol., Jul. 2020.

138

A. Cuker and F. Peyvandi, «Coronavirus disease 2019 (COVID-19): Hypercoagulability», UpToDate, 20-Aug-2020.

139

H. Moldofsky and J. Patcai, «Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study», BMC Neurol., vol. 11, no. 1, p. 37, Dec. 2011.

140

H. W. Wilson, M. Amo-Addae, E. Kenu, O. S. Ilesanmi, D. K. Ameme, and S. O. Sackey, «Post-Ebola Syndrome among Ebola Virus Disease Survivors in Montserrado County, Liberia 2016», Biomed Res. Int., vol. 2018, pp. 1–8, Jun. 2018.

141

T. Yang et al., «The clinical value of cytokines in chronic fatigue syndrome», J. Transl. Med., vol. 17, no. 1, p. 213, Dec. 2019.

142

M. W. Tenforde et al., «Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March — June 2020», MMWR. Morb. Mortal. Wkly. Rep., vol. 69, no. 30, pp. 993–998, Jul. 2020.

143

European Centre for Disease Prevention and Control, «Coronavirus disease 2019 (COVID-19)in the EU/EEA and the UK — eighth update», 2020.

144

Z. Wu and J. M. McGoogan, «Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China», JAMA, vol. 323, no. 13, p. 1239, Apr. 2020.

145

Istituto Superiore di Sanità, «Characteristics of SARS-CoV-2 patients dying in Italy. Report based on available data on May 21st, 2020», 2020.

146

A. C. Fabrizio, Natale, Daniela Ghio, Dario Tarchi, Anne Goujon, «COVID-19 Cases and Case Fatality Rate by age», 2020.

147

F. Perrotta et al., «COVID-19 and the elderly: insights into pathogenesis and clinical decision-making», Aging Clin. Exp. Res., Jun. 2020.

149

M. Zheng et al., «Functional exhaustion of antiviral lymphocytes in COVID-19 patients», Cell. Mol. Immunol., vol. 17, no. 5, pp. 533–535, May 2020.

149

K. Úri et al., «New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) IV: Circulating ACE2 as a Biomarker of Systolic Dysfunction in Human Hypertension and Heart Failure», PLoS One, vol. 9, no. 4, p. e87845, Apr. 2014.

150

C. Tikellis et al., «Developmental expression of ACE2 in the SHR kidney: A role in hypertension?» Kidney Int., vol. 70, no. 1, pp. 34–41, Jul. 2006.

151

M. Nishiga, D. W. Wang, Y. Han, D. B. Lewis, and J. C. Wu, «COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives», Nat. Rev. Cardiol., vol. 17, no. 9, pp. 543–558, Sep. 2020.

152

M. Barnes, A. E. Heywood, A. Mahimbo, B. Rahman, A. T. Newall, and C. R. Macintyre, «Acute myocardial infarction and influenza: a meta-analysis of case — control studies», Heart, vol. 101, no. 21, pp. 1738–1747, Nov. 2015.

153

M. Dolhnikoff et al., «SARS-CoV-2 in cardiac tissue of a child with COVID-19-related multisystem inflammatory syndrome», Lancet Child Adolesc. Heal., Aug. 2020.

154

D. Lindner et al., «Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases», JAMA Cardiol., Jul. 2020.

155

M. Dolhnikoff et al., «SARS-CoV-2 in cardiac tissue of a child with COVID-19-related multisystem inflammatory syndrome», Lancet Child Adolesc. Heal., Aug. 2020.

156

G. Li, H. Li, and J. Lu, «No adequate evidence indicating hypertension as an independent risk factor for COVID-19 severity», Clin. Res. Cardiol., Apr. 2020.

157

L. F. Drager, A. Pio-Abreu, R. D. Lopes, and L. A. Bortolotto, «Is Hypertension a Real Risk Factor for Poor Prognosis in the COVID-19 Pandemic?» Curr. Hypertens. Rep., vol. 22, no. 6, p. 43, Jun. 2020.

158

K. Sriram and P. A. Insel, «Dangers of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence», medRxiv, p. 2020.03.25.20043927, Jan. 2020.

159

H. Kai and M. Kai, «Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors — lessons from available evidence and insights into COVID-19», Hypertens. Res., Apr. 2020.

160

Там же.

161

«Nach Corona-Ausbruch in Baptisten-Gemeinde: Weiterer kirchlicher Infektionsherd», FR.de, 2020. [Online]. Available: https://www.fr.de/frankfurt/frankfurt-am-main-ort28687/frankfurt-corona-coronavirus-infektionen-baptisten-gottesdienst-covid-19-krankenhaus-zr-13773287.html. [Accessed: 31-May-2020].

162

P. de Candia et al., «Type 2 Diabetes: How Much of an Autoimmune Disease?» Front. Endocrinol. (Lausanne)., vol. 10, Jul. 2019.

163

D. T. Graves and R. A. Kayal, «Diabetic complications and dysregulated innate immunity»., Front. Biosci., vol. 13, pp. 1227–39, Jan. 2008.

164

165

J. Lighter et al., «Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission», Clin. Infect. Dis., Apr. 2020.

166

A. Simonnet et al., «High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation», Obesity, Apr. 2020.

167

A. B. Docherty et al., «Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol», medRxiv, p. 2020.04.23.20076042, Jan. 2020.

168

A. E. Dixon and U. Peters, «The effect of obesity on lung function», Expert Rev. Respir. Med., vol. 12, no. 9, pp. 755–767, Sep. 2018.

169

R. A. Watson et al., «Reduction of total lung capacity in obese men: comparison of total intrathoracic and gas volumes», J. Appl. Physiol., vol. 108, no. 6, pp. 1605–1612, Jun. 2010.

170

A. E. Dixon and U. Peters, «The effect of obesity on lung function», Expert Rev. Respir. Med., vol. 12, no. 9, pp. 755–767, Sep. 2018.

171

X. Zhang et al., «Systemic inflammation mediates the detrimental effects of obesity on asthma control», Allergy Asthma Proc., 2017.

172

R. Huttunen and J. Syrjänen, «Obesity and the risk and outcome of infection», Int. J. Obes., vol. 37, no. 3, pp. 333–340, Mar. 2013.

173

UN Women, «COVID-19: Emerging gender data and why it matters», 2020. [Online]. Available: https://data.unwomen.org/resources/covid-19-emerging-gender-data-and-why-it-matters. [Accessed: 05-Jun-2020].

174

G. H. 50/50, «COVID-19 sex-disaggregated data tracker», 2020. [Online]. Available: https://globalhealth5050.org/covid19/sex-disaggregated-data-tracker/. [Accessed: 18-Aug-2020].

175

C. Karagiannidis et al., «Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study», Lancet Respir. Med., Jul. 2020.

176

H. Ueyama et al., «Gender Difference Is Associated With Severity of Coronavirus Disease 2019 Infection: An Insight From a Meta-Analysis», Crit. Care Explor., vol. 2, no. 6, p. e0148, Jun. 2020.

177

M. J. Nasiri et al., «COVID-19 clinical characteristics, and sex-specific risk of mortality: Systematic Review and Meta-analysis», medRxiv, p. 2020.03.24.20042903, Jan. 2020.

178

179

Robert Koch Institute, «Coronavirus Disease 2019(COVID-19)Daily Situation Report of the Robert Koch Institute. 01/06/2020 — UPDATED STATUS FOR GERMANY», 2020.

180

G. H. 50/50, «COVID-19 sex-disaggregated data tracker», 2020. [Online]. Available: https://globalhealth5050.org/covid19/sex-disaggregated-data-tracker/. [Accessed: 18-Aug-2020].

181

C. Vlassoff, «Gender differences in determinants and consequences of health and illness»., J. Health. Popul. Nutr., vol. 25, no. 1, pp. 47–61, Mar. 2007.

182

A. E. Thompson, Y. Anisimowicz, B. Miedema, W. Hogg, W. P. Wodchis, and K. Aubrey-Bassler, «The influence of gender and other patient characteristics on health care-seeking behaviour: a QUALICOPC study», BMC Fam. Pract., vol. 17, no. 1, p. 38, Dec. 2016.

183

S. L. Klein and K. L. Flanagan, «Sex differences in immune responses», Nat. Rev. Immunol., vol. 16, no. 10, pp. 626–638, Oct. 2016.

184

J. E. Fa, J. R. Stewart, L. Lloveras, and J. M. Vargas, «Rabbits and hominin survival in Iberia», J. Hum. Evol., vol. 64, no. 4, pp. 233–241, Apr. 2013.

185

K. S. Singh, «Gender Roles in History: Women as Hunters», Gend. Technol. Dev., vol. 5, no. 1, pp. 113–124, Mar. 2001.

186

M. T. Dorak and E. Karpuzoglu, «Gender Differences in Cancer Susceptibility: An Inadequately Addressed Issue», Front. Genet., vol. 3, 2012.

187

M. McCarthy, «The ‘gender gap’ in autoimmune disease», Lancet, vol. 356, no. 9235, p. 1088, Sep. 2000.

188

L. Yan et al., «An interpretable mortality prediction model for COVID-19 patients», Nat. Mach. Intell., vol. 2, no. 5, pp. 283–288, May 2020.

189

D. M. Del Valle et al., «An inflammatory cytokine signature predicts COVID-19 severity and survival», Nat. Med., Aug. 2020.

190

X. Xu et al., «Effective treatment of severe COVID-19 patients with tocilizumab», Proc. Natl. Acad. Sci., vol. 117, no. 20, pp. 10970–10975, May 2020.

191

G. Gritti et al., «IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study», medRxiv, p. 2020.04.01.20048561, Jan. 2020.

192

W. Gou et al., «Gut microbiota may underlie the predisposition of healthy individuals to COVID-19», medRxiv, p. 2020.04.22.20076091, Jan. 2020.

193

J. Zhao et al., «Relationship between the ABO Blood Group and the COVID-19 Susceptibility», medRxiv, p. 2020.03.11.20031096, Jan. 2020.

194

M. Zietz and N. P. Tatonetti, «Testing the association between blood type and COVID-19 infection, intubation, and death», medRxiv, p. 2020.04.08.20058073, Jan. 2020.

195

D. Ellinghaus et al., «The ABO blood group locus and a chromosome 3 gene cluster associate with SARS-CoV-2 respiratory failure in an Italian-Spanish genome-wide association analysis», medRxiv, p. 2020.05.31.20114991, Jan. 2020.

196

Z. Wang et al., «Influences of ABO blood group, age and gender on plasma coagulation factor VIII, fibrinogen, von Willebrand factor and ADAMTS13 levels in a Chinese population», PeerJ, vol. 5, p. e3156, Mar. 2017.

197

L. Gallinaro et al., «A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor», Blood, vol. 111, no. 7, pp. 3540–3545, Apr. 2008.

198

C. A. Latz et al., «Blood type and outcomes in patients with COVID-19», Ann. Hematol., vol. 99, no. 9, pp. 2113–2118, Sep. 2020.

199

K. Hennig, «(21) Coronavirus-Update: Antikörpertests kommen bald», NDR Info — Das Coronavirus-Update mit Christian Drosten, 2020.

200

C. Menni et al., «Real-time tracking of self-reported symptoms to predict potential COVID-19», Nat. Med., May 2020.

201

UK Department of Health and Social Care, «Statement from the UK Chief Medical Officers on an update to coronavirus symptoms: 18 May 2020», 2020.

202

L. Mao et al., «Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study», medRxiv, p. 2020.02.22.20026500, Jan. 2020.

203

J. Y. Tong, A. Wong, D. Zhu, J. H. Fastenberg, and T. Tham, «The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis», Otolaryngol. Neck Surg., p. 019459982092647, May 2020.

204

D. Pierron et al., «Smell and taste changes are early indicators of the COVID-19 pandemic and political decision effectiveness», Nat. Commun., vol. 11, no. 1, p. 5152, Dec. 2020.

205

«Рост за неделю — больше 40 процентов». О чем говорит динамика ковидных поисковых запросов, Фонтанка. Ру, 12-Oct-2020.

206

A. S. Bhattacharjee, S. V. Joshi, S. Naik, S. Sangle, and N. M. Abraham, «Quantitative assessment of olfactory dysfunction accurately detects asymptomatic COVID-19 carriers», EClinicalMedicine, p. 100575, Oct. 2020.

207

D. H. Brann et al., «Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia», Sci. Adv., vol. 6, no. 31, p. eabc5801, Jul. 2020.

208

Y. Lee, P. Min, S. Lee, and S.-W. Kim, «Prevalence and Duration of Acute Loss of Smell or Taste in COVID-19 Patients», J. Korean Med. Sci., vol. 35, no. 18, 2020.

209

E. N. Antonova, C. E. Rycroft, C. S. Ambrose, T. Heikkinen, and N. Principi, «Burden of paediatric influenza in Western Europe: a systematic review», BMC Public Health, vol. 12, no. 1, p. 968, Dec. 2012.

210

V. Usonis et al., «Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for influenza vaccination in children», BMC Infect. Dis., vol. 10, no. 1, p. 168, Dec. 2010.

211

WHO, «Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)», 28-Feb-2020.

212

J. S. Brownstein, K. P. Kleinman, and K. D. Mandl, «Identifying Pediatric Age Groups for Influenza Vaccination Using a Real-Time Regional Surveillance System», Am. J. Epidemiol., vol. 162, no. 7, pp. 686–693, Oct. 2005.

213

E. Miller, K. Hoschler, P. Hardelid, E. Stanford, N. Andrews, and M. Zambon, «Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study», Lancet, vol. 375, no. 9720, pp. 1100–1108, Mar. 2010.

214

D. F. Gudbjartsson et al., «Spread of SARS-CoV-2 in the Icelandic Population», N. Engl. J. Med., vol. 382, no. 24, pp. 2302–2315, Jun. 2020.

215

F.-C. Zhu et al., «Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial», Lancet, vol. 395, no. 10240, pp. 1845–1854, Jun. 2020.

216

R. M. Viner et al., «Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults: A Systematic Review and Meta-analysis.,» JAMA Pediatr., Sep. 2020.

217

I. Dattner et al., «The role of children in the spread of COVID-19: Using household data from Bnei Brak, Israel, to estimate the relative susceptibility and infectivity of children», medRxiv, p. 2020.06.03.20121145, Jan. 2020.

218

219

C. M. Szablewski et al., «SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp — Georgia, June 2020», MMWR. Morb. Mortal. Wkly. Rep., vol. 69, no. 31, pp. 1023–1025, Aug. 2020.

220

«Första resultaten om antikroppar efter genomgången covid-19 hos blodgivare», Folkhälsomyndighetens, 16-Jun-2020.

221

Лыскина Г. А., Бокерия О. Л., Сатюкова А. С., Ширинская О. Г., Леонтьева А. А. и Гагарина Н. В. Поражение коронарных артерий у детей с синдромом Кавасаки в Москве по данным 10-летнего наблюдения. XX Всероссийский съезд сердечно-сосудистых хирургов, 2014.

222

J. Toubiana et al., «Outbreak of Kawasaki disease in children during COVID-19 pandemic: a prospective observational study in Paris, France», medRxiv, p. 2020.05.10.20097394, Jan. 2020.

223

C. Rosat Consiglio et al., «The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19», medRxiv, p. 2020.07.08.20148353, Jan. 2020.

224

R. Wölfel et al., «Virological assessment of hospitalized patients with COVID-2019», Nature, Apr. 2020.

225

C.-G. Huang et al., «Culture-Based Virus Isolation To Evaluate Potential Infectivity of Clinical Specimens Tested for COVID-19», J. Clin. Microbiol., vol. 58, no. 8, Jun. 2020.

226

T. C. Jones et al., «An analysis of SARS-CoV-2 viral load by patient age», medRxiv, p. 2020.06.08.20125484, Jan. 2020.

227

«Children have a similar prevalence of COVID-19 antibodies to adults, but more than 99 % have mild symptoms», Sant Joan de Déu Barcelona, 09-Jun-2020.

228

«Första resultaten från pågående undersökning av antikroppar för covid-19-virus», Folkhälsomyndighetens, 18-May-2020.

229

«Första resultaten om antikroppar efter genomgången covid-19 hos blodgivare», Folkhälsomyndighetens, 16-Jun-2020.

230

V. Moorthy, A. M. Henao Restrepo, M.-P. Preziosi, and S. Swaminathan, «Data sharing for novel coronavirus (COVID-19)», Bull. World Health Organ., vol. 98, no. 3, pp. 150–150, Mar. 2020.

231

Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, «[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]»., Zhonghua Jie He He Hu Xi Za Zhi, vol. 43, no. 3, pp. 185–188, Mar. 2020.

232

«Руководство по лечению и поддерживающей терапии пациентов с коронавирусной инфекцией COVID-19, выпуск марта 2020 г»., ЛОМБАРДИЯ, SIMIT Итальянское Общество Инфекционных и Тропических болезней ОТДЕЛ РЕГИОНА. [Online]. Available: https://h-clinic.ru/upload/%D0%9D%D0%B5%D0%BE%D1%84%D0%B8%D1%86%D0%B8%D0%B0%D0%BB%D1%8C%D0%BD%D1%8B%D0%B8%CC%86%20%D0%BF%D0%B5%D1%80%D0%B5%D0%B2%D0%BE%D0%B4%20%D0%A0%D1%83%D0%BA%D0%BE%D0%B2%D0%BE%D0%B4%D1%81%D1%82%D0%B2%D0%B0%20%D0%BF%D0%BE%20%D0%BB%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D1%8E%20%D0%BF%D0%B0%D1%86%D0%B8%D0%B5%D0%BD%D1%82%D0%BE%D0%B2%20%D1%81%2 °COVID-19%20%D0%B2%20%D0%98%D1%82%D0%B0%D0%BB%D0%B8%D0%B8.pdf.

233

C. Mary, «Sound and Fury in the Microbiology Lab», Science, vol. 335, no. 6072, pp. 1033–1035, Mar. 2012.

234

«WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19», WHO, 04-Jul-2020.

235

P. Gautret et al., «Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial», Int. J. Antimicrob. Agents, p. 105949, Mar. 2020.

236

P. Gautret et al., «Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 8 °COVID-19 patients with at least a six-day follow up: A pilot observational study», Travel Med. Infect. Dis., vol. 34, p. 101663, Mar. 2020.

237

Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 7 (03.06.2020) // Министерство здравоохранения Российской Федерации, 2020. [Online]. Available: https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/584/original/03062020_%D0%9CR_COVID-19_v7.pdf?fbclid=IwAR1p266v_Ok6Hw0Xjw5nRVtJopPRDKdpP1nEMDmDcvHl0ug9QZPo6-mV80c.

238

C. P. Skipper et al., «Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19», Ann. Intern. Med., pp. M20–4207, Jul. 2020.

239

N. W. Schluger, «The Saga of Hydroxychloroquine and COVID-19: A Cautionary Tale», Ann. Intern. Med., pp. M20–5041, Jul. 2020.

240

FDA, «Letter revoking EUA for chloroquine phosphate and hydroxychloroquine sulfate», 2020.

241

M. R. Mehra, S. S. Desai, F. Ruschitzka, and A. N. Patel, «RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis», Lancet, May 2020.

242

«Department of Error», Lancet, May 2020.

243

«Surgisphere: mass audit of papers linkgd to firm behind hydroxychloroquine Lancet study scandal», The Guardian, 10-Jun-2020.

244

J. Watson and et al., «Open letter to MR Mehra, SS Desai, F Ruschitzka, and AN Patel, authors of‘Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis’. Lancet. 2020 May 22: S0140–6736(20)31180–6. doi: 10.1016/», 2020.

245

The Lancet Editors, «Expression of concern: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis», Lancet, vol. 395, no. 10240, p. e102, Jun. 2020.

246

M. R. Mehra, F. Ruschitzka, and A. N. Patel, «Retraction — Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis», Lancet, vol. 395, no. 10240, p. 1820, Jun. 2020.

247

M. R. Mehra, S. S. Desai, S. Kuy, T. D. Henry, and A. N. Patel, «Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19», N. Engl. J. Med., vol. 382, no. 25, p. e102, Jun. 2020.

248

M. R. Mehra, S. S. Desai, S. Kuy, T. D. Henry, and A. N. Patel, «Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007621»., N. Engl. J. Med., vol. 382, no. 26, pp. 2582–2582, Jun. 2020.

249

P. Pradhan et al., «Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag», bioRxiv, p. 2020.01.30.927871, Jan. 2020.

250

M. K. Lo et al., «GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses», Sci. Rep., vol. 7, no. 1, p. 43395, Mar. 2017.

251

R. T. Eastman et al., «Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19», ACS Cent. Sci., vol. 6, no. 5, pp. 672–683, May 2020.

252

A. Feuerstein, «Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment», STAT News, 16-Apr-2020.

253

«NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19», NIH, 29-Apr-2020.

254

J. H. Beigel et al., «Remdesivir for the Treatment of Covid-19 — Preliminary Report», N. Engl. J. Med., p. NEJMoa2007764, May 2020.

255

Y. Wang et al., «Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial», Lancet, vol. 395, no. 10236, pp. 1569–1578, May 2020.

256

FDA, «Remdesevir Emergency Use Authorization for Potential COVID-19 Treatment», 01-May-2020.

257

«Anti-influenza drug Avigan® Tablet Meets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 patients», FUJIFILM Toyama Chemical Co., Ltd., 23-Sep-2020.

258

Т. А. Руженцова et al., «Возможности этиотропной терапии коронавирусной инфекции, вызванной SARS-CoV-2, у амбулаторных пациентов», Медицинский оппонент, vol. 1, no. 9, pp. 48–58, 2020.

259

260

J. H. Beigel et al., «Remdesivir for the Treatment of Covid-19 — Preliminary Report», N. Engl. J. Med., p. NEJMoa2007764, May 2020.

261

262

O.-M. J. Benhamou, M. Jacobs, J. Drew, S. Geva, M. Waldman, and O. Kalchiem-Dekel, «The Use of Interferons in Respiratory Diseases», Curr. Respir. Med. Rev., vol. 9, no. 5, 2013.

263

«COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines»., National Institutes of Health, 2020. [Online]. Available: https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf. [Accessed: 21-Jun-2020].

264

«Management of a possible case of COVID-19. Version 13. Revised 31 July 2020», Public Health England, 2020. [Online]. Available: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/906096/COVID-19_flow_chart.pdf. [Accessed: 04-Sep-2020].

265

T. Feldt and T. Guggemos, Wolfgang Heim, Katrin Klug, Bettina Lehnert, Regine Lübbert, Christoph Niebank, Michaela Pfäfflin, Frieder Rothfuss, Katja Schmiedel, Stefan Stegemann, Miriam S. Stich, August Wolf, «Hinweise zu Erkennung, Diagnostik und Therapie von Patienten mit COVID-19. Stand: 06.08.2020», Ständiger Arbeitskreis der Kompetenz- und Behandlungszentren für Krankheiten durch hochpathogene Erreger am Robert Koch-Institut, 2020.

266

267

268

L. Fardet, I. Petersen, and I. Nazareth, «Common Infections in Patients Prescribed Systemic Glucocorticoids in Primary Care: A Population-Based Cohort Study», PloS Med., vol. 13, no. 5, p. e1002024, May 2016.

269

T. Feldt and T. Guggemos, Wolfgang Heim, Katrin Klug, Bettina Lehnert, Regine Lübbert, Christoph Niebank, Michaela Pfäfflin, Frieder Rothfuss, Katja Schmiedel, Stefan Stegemann, Miriam S. Stich, August Wolf, «Hinweise zu Erkennung, Diagnostik und Therapie von Patienten mit COVID-19. Stand: 06.08.2020», Ständiger Arbeitskreis der Kompetenz- und Behandlungszentren für Krankheiten durch hochpathogene Erreger am Robert Koch-Institut, 2020.

270

«Clinical management of COVID-19: interim guidance 27 May 2020», WHO, 27-May-2020.

271

C. D. Russell, J. E. Millar, and J. K. Baillie, «Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury», Lancet, vol. 395, no. 10223, pp. 473–475, Feb. 2020.

272

The RECOVERY Collaborative Group, «Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report», N. Engl. J. Med., p. NEJMoa2021436, Jul. 2020.

273

P. Horby et al., «Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report», medRxiv, p. 2020.06.22.20137273, Jan. 2020.

274

«FDA Issues Emergency Use Authorization for Convalescent Plasma as Potential Promising COVID-19 Treatment, Another Achievement in Administration’s Fight Against Pandemic», FDA, 23-Aug-2020.

275

S. Pandey and G. N. Vyas, «Adverse effects of plasma transfusion», Transfusion, vol. 52, pp. 65S-79S, May 2012.

276

A. Agarwal et al., «Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial)», medRxiv, p. 2020.09.03.20187252, Jan. 2020.

277

A. Dasgupta, «Indian Study Shows No Survival Benefit of Plasma in COVID-19», The Scientist, 15-Sep-2020.

278

279

280

The RECOVERY Collaborative Group, «Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report», N. Engl. J. Med., p. NEJMoa2021436, Jul. 2020.

281

«NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19», NIH, 29-Apr-2020.

282

A. E. Thompson, B. L. Ranard, Y. Wei, and S. Jelic, «Prone Positioning in Awake, Nonintubated Patients With COVID-19 Hypoxemic Respiratory Failure», JAMA Intern. Med., Jun. 2020.

283

J. Wise, «Covid-19 and thrombosis: what do we know about the risks and treatment?» BMJ, p. m2058, May 2020.

284

B. Greenwood, «The contribution of vaccination to global health: past, present and future», Philos. Trans. R. Soc. B Biol. Sci., vol. 369, no. 1645, p. 20130433, Jun. 2014.

285

H. Holzmann, H. Hengel, M. Tenbusch, and H. W. Doerr, «Eradication of measles: remaining challenges», Med. Microbiol. Immunol., vol. 205, no. 3, pp. 201–208, Jun. 2016.

286

E. R. Miller, P. L. Moro, M. Cano, and T. T. Shimabukuro, «Deaths following vaccination: What does the evidence show?» Vaccine, vol. 33, no. 29, pp. 3288–3292, Jun. 2015.

287

M. O’Ryan, «Rotavirus Vaccines: a story of success with challenges ahead», F1000Research, vol. 6, p. 1517, Aug. 2017.

288

«WHO Target Product Profiles for COVID-19 Vaccines. Version 3–29, April 2020», WHO, 09-Apr-2020.

289

D. K. Chu et al., «Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis», Lancet, vol. 395, no. 10242, pp. 1973–1987, Jun. 2020.

290

L. M. McNamee, M. J. Walsh, and F. D. Ledley, «Timelines of translational science: From technology initiation to FDA approval», PLoS One, vol. 12, no. 5, p. e0177371, May 2017.

291

I. A. Hamilton, «Bill Gates is helping fund new factories for 7 potential coronavirus vaccines, even though it will waste billions of dollars», Business Insider, 03-Apr-2020.

292

C. Cookson, «UK to test vaccines on volunteers deliberately infected with Covid-19», Financial Times, 23-Sep-2020.

293

S. E. Lederer, «The Challenges of Challenge Experiments», N. Engl. J. Med., vol. 371, no. 8, pp. 695–697, Aug. 2014.

294

Дьяконова О., Рейтер С. Ученые в России испытали вакцину от Covid на себе. Фармкомпании сочли это нарушением // BBC, 22-May-2020.

295

T. Ura, K. Okuda, and M. Shimada, «Developments in Viral Vector-Based Vaccines», Vaccines, vol. 2, no. 3, pp. 624–641, Jul. 2014.

296

Рейтер С., Ершов А. Первое большое интервью создатель российской вакцины от коронавируса Денис Логунов дал «Медузе». Он рассказал, стоит ли ждать прививок к сентябрю 2020 года // Meduza, 23-Jul-2020.

297

D. Y. Logunov et al., «Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia», Lancet, vol. 396, no. 10255, pp. 887–897, Sep. 2020.

298

Фармкомпании призвали Минздрав отложить регистрацию вакцины от COVID-19 // РБК, 10-Aug-2020.

299

Минздрав России выдал Центру Гамалеи разрешение на проведение пострегистрационного клинического исследования вакцины от коронавируса // Министерство здравоохранения Российской Федерации, 25-Aug-2020.

300

Первыми получат отечественную вакцину от коронавируса врачи и учителя // Медвестник, 01-Aug-2020.

301

H. L. Robinson and T. M. Pertmer, «DNA vaccines for viral infections: Basic studies and applications», 2000, pp. 1–74.

302

K. S. Corbett et al., «SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness», Nature, Aug. 2020.

303

D. Wrapp et al., «Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation», Science, vol. 367, no. 6483, pp. 1260–1263, Mar. 2020.

304

I. Kristensen, P. Aaby, H. Jensen, and P. Fine, «Routine vaccinations and child survival: follow up study in Guinea-Bissau, West Africa Commentary: an unexpected finding that needs confirmation or rejection», BMJ, vol. 321, no. 7274, pp. 1435–1435, Dec. 2000.

305

J. Higgins, K. Soares-Weiser, and A. Reingold, «Systematic review of the non-specific effects of BCG, DTP and measles containing vaccines», 2014.

306

J. P. T. Higgins et al., «Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review», BMJ, p. i5170, Oct. 2016.

307

R. J. W. Arts et al., «BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity», Cell Host Microbe, vol. 23, no. 1, pp. 89–100.e5, Jan. 2018.

308

F. Gallais et al., «Intrafamilial Exposure to SARS-CoV-2 Induces Cellular Immune Response without Seroconversion», medRxiv, p. 2020.06.21.20132449, Jan. 2020.

309

T. Sekine et al., «Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19», bioRxiv, p. 2020.06.29.174888, Jan. 2020.

310

K. K.-W. To et al., «COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing», Clin. Infect. Dis., Aug. 2020.

311

R. L. Tillett et al., «Genomic evidence for reinfection with SARS-CoV-2: a case study», Lancet Infect. Dis., Oct. 2020.

312

B. Prado-Vivar et al., «COVID-19 Re-Infection by a Phylogenetically Distinct SARS-CoV-2 Variant, First Confirmed Event in South America»., SSRN Electron. J., 2020.

313

M. Mulder et al., «Reinfection of SARS-CoV-2 in an immunocompromised patient: a case report», Clin. Infect. Dis., Oct. 2020.

314

Там же.

315

E. Brochot et al., «Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers», medRxiv, p. 2020.05.12.20098236, Jan. 2020.

316

J. Wu et al., «SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19», medRxiv, p. 2020.07.21.20159178, Jan. 2020.

317

R. Wang, Y. Hozumi, C. Yin, and G.-W. Wei, «Decoding SARS-CoV-2 Transmission and Evolution and Ramifications for COVID-19 Diagnosis, Vaccine, and Medicine», J. Chem. Inf. Model., p. acs.jcim.0c00501, Jun. 2020.

318

«Researchers develop first diagnostic test for novel coronavirus in China», German Center for Infection Research, 16-Jan-2020.

319

M. R. Tom and M. J. Mina, «To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold Value», Clin. Infect. Dis., May 2020.

320

A. Ault, «CDC to Urge Against Repeat Testing After COVID Illness Resolves», 16-Jul-2020.

321

L. Azzi et al., «Saliva is a reliable tool to detect SARS-CoV-2», J. Infect., Apr. 2020.

322

K. K.-W. To et al., «Consistent Detection of 2019 Novel Coronavirus in Saliva», Clin. Infect. Dis., Feb. 2020.

323

A. L. Wyllie et al., «Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2», N. Engl. J. Med., vol. 383, no. 13, pp. 1283–1286, Sep. 2020.

324

«(57) Coronavirus-Update: Goldstandard bleibt der PCR-Test», NDR Info — Das Coronavirus-Update mit Christian Drosten, 24-Sep-2020.

325

Там же.

326

Q.-X. Long et al., «Antibody responses to SARS-CoV-2 in patients with COVID-19», Nat. Med., vol. 26, no. 6, pp. 845–848, Jun. 2020.

327

«Interim Guidelines for COVID-19 Antibody Testing», CDC, 01-Aug-2020.

328

Q.-X. Long et al., «Antibody responses to SARS-CoV-2 in patients with COVID-19», Nat. Med., vol. 26, no. 6, pp. 845–848, Jun. 2020.

329

J. Seow et al., «Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection», medRxiv, p. 2020.07.09.20148429, Jan. 2020.

330

W.-C. Cao, W. Liu, P.-H. Zhang, F. Zhang, and J. H. Richardus, «Disappearance of Antibodies to SARS-Associated Coronavirus after Recovery», N. Engl. J. Med., vol. 357, no. 11, pp. 1162–1163, Sep. 2007.

331

H. Mo et al., «Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance», Respirology, vol. 11, no. 1, pp. 49–53, Jan. 2006.

332

A. W. D. Edridge et al., «Coronavirus protective immunity is short-lasting», medRxiv, p. 2020.05.11.20086439, Jan. 2020.

333

K. K.-W. To et al., «COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing», Clin. Infect. Dis., Aug. 2020.

334

B. Prado-Vivar et al., «COVID-19 Re-Infection by a Phylogenetically Distinct SARS-CoV-2 Variant, First Confirmed Event in South America»., SSRN Electron. J., 2020.

335

336

«VIDEO: COVID-19 reinfection, Director of Nevada State Public Health Lab», ABC 6 NEWS, 02-Sep-2020.

337

E. Cohen, «Prominent scientists have bad news for the White House about coronavirus antibody tests», CNN, 15-Apr-2020. [Online]. Available: https://edition.cnn.com/2020/04/14/health/coronavirus-antibody-tests-scientists/. [Accessed: 16-Jul-2020].

338

J. A. Usher-Smith, S. J. Sharp, and S. J. Griffin, «The spectrum effect in tests for risk prediction, screening, and diagnosis», BMJ, p. i3139, Jun. 2016.

339

W. Wang et al., «Detection of SARS-CoV-2 in Different Types of Clinical Specimens», JAMA, Mar. 2020.

340

D. B. Larremore et al., «Test sensitivity is secondary to frequency and turnaround time for COVID-19 surveillance», medRxiv, p. 2020.06.22.20136309, Jan. 2020.

341

«Coronavirus (COVID-19) Update: FDA Informs Public About Possible Accuracy Concerns with Abbott ID NOW Point-of-Care Test», FDA, 14-May-2020.

342

«New York City Coronavirus Map and Case Count», The New York Times, 2020. [Online]. Available: https://www.nytimes.com/interactive/2020/nyregion/new-york-city-coronavirus-cases.html. [Accessed: 17-Jul-2020].

343

«India coronavirus: Rapid testing paused over China kit issues», BBC, 22-Apr-2020.

344

«Coronavirus test kits withdrawn in Spain over poor accuracy rate», The Guardian, 27-Mar-2020.

345

«The Global Economic Outlook During the COVID-19 Pandemic: A Changed World», The World Bank, 08-Jun-2020.

346

«Mission summary: WHO Field Visit to Wuhan, China 20–21 January 2020», WHO, 22-Jan-2020.

347

Q. Li et al., «Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus — Infected Pneumonia», N. Engl. J. Med., vol. 382, no. 13, pp. 1199–1207, Mar. 2020.

348

«Coronavirus was already in Italy by December, waste water study finds», BBC, 19-Jun-2020.

349

ВОЗ объявила пандемию нового коронавируса // BBC, 11-Mar-2020.

350

«Read President Trump’s Speech on Coronavirus Pandemic: Full Transcript», The New York Times, 11-Mar-2020.

351

«Letter from President Donald J. Trump on Emergency Determination Under the Stafford Act», WhiteHouse.gov, 13-Mar-2020.

352

A. B. Komissarov et al., «Genomic epidemiology of the early stages of SARS-CoV-2 outbreak in Russia», medRxiv, p. 2020.07.14.20150979, Jan. 2020.

353

I. Ritov and J. Baron, «Status-quo and omission biases», J. Risk Uncertain., vol. 5, no. 1, Feb. 1992.

354

Информационные бюллетени. Корь // ВОЗ, 2018. [Online]. Available: https://www.who.int/ru/news-room/fact-sheets/detail/measles. [Accessed: 18-Jul-2020].

355

F. Dorn et al., «Das gemeinsame Interesse von Gesundheit und Wirtschaft: Eine Szenarienrechnung zur Eindämmung der Corona-Pandemie», ifo Schnelld. Digit., vol. 6, 2020.

356

Якутенко И. Воля и самоконтроль. Как гены и мозг мешают нам бороться с соблазнами. — М.: Альпина нон-фикшн, 2018.

357

T. Jefferson et al., «Physical interventions to interrupt or reduce the spread of respiratory viruses. Part 1 — Face masks, eye protection and person distancing: systematic review and meta-analysis», medRxiv, p. 2020.03.30.20047217, Jan. 2020.

358

359

M. Gandhi and G. W. Rutherford, «Facial Masking for Covid-19 — Potential for ‘Variolation’ as We Await a Vaccine», N. Engl. J. Med., p. NEJMp2026913, Sep. 2020.

360

R. Zhang, Y. Li, A. L. Zhang, Y. Wang, and M. J. Molina, «Identifying airborne transmission as the dominant route for the spread of COVID-19», Proc. Natl. Acad. Sci., vol. 117, no. 26, pp. 14857–14863, Jun. 2020.

361

M. Hendrix, C. Walde, K. Findley, and R. Trotman, «Absence of Apparent Transmission of SARS-CoV-2 from Two Stylists After Exposure at a Hair Salon with a Universal Face Covering Policy», MMWR Morb Mortal Wkly Rep, vol. 69, pp. 930–932, 2020.

362

N. R. Jones, Z. U. Qureshi, R. J. Temple, J. P. J. Larwood, T. Greenhalgh, and L. Bourouiba, «Two metres or one: what is the evidence for physical distancing in covid-19?» BMJ, p. m3223, Aug. 2020.

363

364

Z. Qureshi, N. Jones, R. Temple, J. P. Larwood, T. Greenhalgh, and L. Bourouiba, «What is the evidence to support the 2-metre social distancing rule to reduce COVID-19 transmission?» Cent. Evidence-Based Med. 22.06.2020, 2020.

365

«When to wear gloves», CDC, 2020. [Online]. Available: https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html. [Accessed: 19-Jul-2020].

366

«Use of gloves in healthcare and non-healthcare settings in the context of the COVID-19 pandemic», European Centre for Disease Prevention and Control, 02-Jul-2020.

367

M. J. Cashore et al., «COVID-19 Mathematical Modeling for Cornell’s Fall Semester», Cornell University, 15-Jun-2020.

368

M. R. Tom and M. J. Mina, «To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold Value», Clin. Infect. Dis., May 2020.

369

«(57) Coronavirus-Update: Goldstandard bleibt der PCR-Test», NDR Info — Das Coronavirus-Update mit Christian Drosten, 24-Sep-2020.

370

FDA, «Coronavirus (COVID-19) Update: FDA Informs Public About Possible Accuracy Concerns with Abbott ID NOW Point-of-Care Test», 14-May-2020.

371

D. B. Larremore et al., «Test sensitivity is secondary to frequency and turnaround time for COVID-19 surveillance», medRxiv, p. 2020.06.22.20136309, Jan. 2020.

372

I. Yelin et al., «Evaluation of COVID-19 RT-qPCR test in multi-sample pools», Clin. Infect. Dis., May 2020.

373

L. Mutesa et al., «A strategy for finding people infected with SARS-CoV-2: optimizing pooled testing at low prevalence», Apr. 2020.

374

L. Ferretti et al., «Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing», Science, vol. 368, no. 6491, p. eabb6936, May 2020.

375

M. E. Kretzschmar, G. Rozhnova, M. C. J. Bootsma, M. van Boven, J. H. H. M. van de Wijgert, and M. J. M. Bonten, «Impact of delays on effectiveness of contact tracing strategies for COVID-19: a modelling study», Lancet Public Heal., Jul. 2020.

376

377

J. O. Lloyd-Smith, S. J. Schreiber, P. E. Kopp, and W. M. Getz, «Superspreading and the effect of individual variation on disease emergence», Nature, vol. 438, no. 7066, pp. 355–359, Nov. 2005.

378

M. Hartfield and S. Alizon, «Introducing the Outbreak Threshold in Epidemiology», PLoS Pathog., vol. 9, no. 6, p. e1003277, Jun. 2013.

379

M. Hartfield and S. Alizon, «Introducing the Outbreak Threshold in Epidemiology», PLoS Pathog., vol. 9, no. 6, p. e1003277, Jun. 2013.

380

J. O. Lloyd-Smith, S. J. Schreiber, P. E. Kopp, and W. M. Getz, «Superspreading and the effect of individual variation on disease emergence», Nature, vol. 438, no. 7066, pp. 355–359, Nov. 2005.

381

M. A. Benitez, «‘Patient zero’ believed he did not have Sars, inquiry told», 14-Dec-2020.

382

M. Hartfield and S. Alizon, «Introducing the Outbreak Threshold in Epidemiology», PLoS Pathog., vol. 9, no. 6, p. e1003277, Jun. 2013.

383

«Spike in South Korean infections linkld to one man’s night out», Deutsche Welle, 2020. [Online]. Available: https://p.dw.com/p/3bzq3. [Accessed: 31-May-2020].

384

385

A. V. Tkachenko, S. Maslov, A. Elbanna, G. Wong, Z. Weiner, and N. Goldenfeld, «Persistent heterogeneity not short-term overdispersion determines herd immunity to COVID-19», medRxiv, p. 2020.07.26.20162420, Jan. 2020.

386

X. Guo et al., «Long-Term Persistence of IgG Antibodies in SARS-CoV Infected Healthcare Workers», medRxiv, p. 2020.02.12.20021386, Jan. 2020.

387

A. W. D. Edridge et al., «Coronavirus protective immunity is short-lasting», medRxiv, p. 2020.05.11.20086439, Jan. 2020.

388

K. K.-W. To et al., «COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing», Clin. Infect. Dis., Aug. 2020.

389

M. Mulder et al., «Reinfection of SARS-CoV-2 in an immunocompromised patient: a case report», Clin. Infect. Dis., Oct. 2020.

390

R. L. Tillett et al., «Genomic evidence for reinfection with SARS-CoV-2: a case study», Lancet Infect. Dis., Oct. 2020.

391

B. Prado-Vivar et al., «COVID-19 Re-Infection by a Phylogenetically Distinct SARS-CoV-2 Variant, First Confirmed Event in South America»., SSRN Electron. J., 2020.